To explore substrates of RSK and downstream signaling pathways mediated by RSK in FLT3-ITD-positive AML cells, we first examined time-course effects of the most specific RSK inhibitor, LJH685, on phosphorylation of candidates of substrates in MV4-11 cell. Here, RPS6KA3 is linked to acute myeloid leukemia.